MYOS RENS Technology Inc.
If you purchased MYOS RENS Technology Inc. securities and would like to join the action, please click "Join This Action" below.
MYOS RENS MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE MERGER OF MYOS RENS TECHNOLOGY INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM
July 2, 2020.
New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger between MYOS RENS Technology Inc. (NASDAQ: MYOS) and MedAvail, Inc. is fair to MYOS RENS shareholders. On behalf of MYOS RENS shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
The investigation concerns whether MYOS RENS and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to: (1) obtain the best possible consideration for MYOS RENS shareholders; and (2) disclose all material information necessary for MYOS RENS shareholders to adequately assess and value the proposed transaction.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.